Trial · NCT00605072
The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial
NCT00605072, Phase 2, Completed, University of Southern California; results first posted 2013-02-15
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial. Trials, record NCT00605072. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00605072
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial
- NCT number
- NCT00605072
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 53 participants, actual
- Lead sponsor
- University of Southern California
- Conditions
- Cognitive Impairment, Hypertension, Aging
- Interventions
- candesartan, lisinopril, hydrochlorothiazide, nifedipine, long acting, metoprolol, long-acting
- First posted
- 2008-01-30
- Last updated
- 2013-02-15
- Results first posted
- 2013-02-15
- Limitations and caveats
The main limitation is the small sample size. The validity of TCD measurements as an index of cerebral blood flow is based on the assumption that cerebral vessel diameters are constant but we didn't have brain imaging to validate this assumption.
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cognitive Assessment: Trail Making Test Part B | Baseline-12 months | This test requires the connection of sequentially numbered circles (A), and the connection of circles marked by numbers and letters in alternating sequence (B). This test is considered a benchmark of executive function. The test score is the time required to complete the task in seconds. |
| Primary | Cognitive Assessment: Hopkins Verbal Learning- Immediate Recall | Baseline-12 months | This is a 12-item list learning test in which individuals are presented three learning and recall trials followed by a delayed recall and 24 item recognition test. The HVLT-R has been identified as an ideal memory measure for elderly patients, and appropriate reliability and validity have been shown in older individuals. The test score is the number of correct answers in the delayed recall ( score range 0-12) |
| Primary | Cognitive Assessment: Forward Digit Span Test | Baseline-12 months | This test consists of series of digits of increasing length, some of which are recited as presented, and some of which are to be recited in reversed order. The forward digit span score ranges from 0 (ie cannot repeat two digits) to 8 ( participant can repeat up to 8 digits) |
| Secondary | Blood Pressure Outcome: Systolic BP | Baseline-12 months | Blood pressure was measured as follows: the participant was in the sitting position, rested for 5 minutes, no caffeine or smoking 2 hours prior to measurement, using appropriate cuff size (covering 60% of upper arm length and 80% of arm circumference), correct cuff placement (1-2 inches above brachial pulse on bare arm), and the bell of the stethoscope. The systolic blood pressure was defined as the pressure corresponding to the first korotkoff sounds (K1) and the diastolic as the pressure corresponding to the last korotkoff sound (K5). Blood pressure was measured in both arms and recorded |
| Secondary | Blood Flow Velocity, Sitting | Baseline-12 months | This reports the change in the least square mean from baseline to 12 months, adjusted for age |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Cognitive Assessment: Trail Making Test Part B | Baseline-12 months | seconds | LEAST_SQUARES_MEAN | |
| SECONDARY | Blood Pressure Outcome: Systolic BP | Baseline-12 months | mm Hg | LEAST_SQUARES_MEAN | |
| SECONDARY | Blood Flow Velocity, Sitting | Baseline-12 months | cm/sec | LEAST_SQUARES_MEAN | |
| PRIMARY | Cognitive Assessment: Hopkins Verbal Learning- Immediate Recall | Baseline-12 months | number words remembered | LEAST_SQUARES_MEAN | |
| PRIMARY | Cognitive Assessment: Forward Digit Span Test | Baseline-12 months | number of digits repeated | LEAST_SQUARES_MEAN |
Source ClinicalTrials.gov
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Cognitive Assessment: Trail Making Test Part B | ACEI (Lisinopril) | -14 | Standard Error 9 | seconds | |
| Cognitive Assessment: Trail Making Test Part B | ARB (Candesartan) | 17 | Standard Error 10 | seconds | |
| Cognitive Assessment: Trail Making Test Part B | HCTZ | 4 | Standard Error 9 | seconds | |
| Blood Pressure Outcome: Systolic BP | ACEI (Lisinopril) | 28 | Standard Error 5 | mm Hg | |
| Blood Pressure Outcome: Systolic BP | ARB (Candesartan) | 27 | Standard Error 5 | mm Hg | |
| Blood Pressure Outcome: Systolic BP | HCTZ | 21 | Standard Error 5 | mm Hg | |
| Blood Flow Velocity, Sitting | ACEI (Lisinopril) | -0.3 | Standard Error 1.5 | cm/sec | |
| Blood Flow Velocity, Sitting | ARB (Candesartan) | -2.85 | Standard Error 1.71 | cm/sec | |
| Blood Flow Velocity, Sitting | HCTZ | 0.35 | Standard Error 1.68 | cm/sec | |
| Cognitive Assessment: Hopkins Verbal Learning- Immediate Recall | ACEI (Lisinopril) | -1 | Standard Error 1 | number words remembered |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 results by groupParticipant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Lisinopril | 18 | |
| Overall Study | STARTED | Candesartan | 20 | |
| Overall Study | STARTED | HCTZ | 15 | |
| Overall Study | COMPLETED | Lisinopril | 11 | |
| Overall Study | COMPLETED | Candesartan | 9 | |
| Overall Study | COMPLETED | HCTZ | 11 | |
| Overall Study | NOT COMPLETED | Lisinopril | 7 | |
| Overall Study | NOT COMPLETED | Candesartan | 11 | |
| Overall Study | NOT COMPLETED | HCTZ | 4 |
Source ClinicalTrials.gov
Adverse events15
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dizziness | Nervous system disorders | ACEI (Lisinopril) | 5 | 18 | |
| other | Dizziness | Nervous system disorders | ARB (Candesartan) | 6 | 20 | |
| other | Dizziness | Nervous system disorders | HCTZ | 6 | 15 | |
| other | Weakness or Fatigue | Nervous system disorders | ACEI (Lisinopril) | 3 | 18 | |
| other | Weakness or Fatigue | Nervous system disorders | ARB (Candesartan) | 1 | 20 | |
| other | Weakness or Fatigue | Nervous system disorders | HCTZ | 1 | 15 | |
| other | Fall, non-injurious | Nervous system disorders | ACEI (Lisinopril) | 4 | 18 | |
| other | Fall, non-injurious | Nervous system disorders | ARB (Candesartan) | 1 | 20 | |
| other | Fall, non-injurious | Nervous system disorders | HCTZ | 2 | 15 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | ACEI (Lisinopril) | 5 | 18 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | ACEI (Lisinopril) | ||
| Total, all-cause mortality | ARB (Candesartan) | ||
| Total, all-cause mortality | HCTZ | ||
| Total, other adverse events | ACEI (Lisinopril) | 5 | 18 |
| Total, other adverse events | ARB (Candesartan) | 6 | 20 |
| Total, other adverse events | HCTZ | 6 | 15 |
| Total, serious adverse events | ACEI (Lisinopril) | 0 | 18 |
| Total, serious adverse events | ARB (Candesartan) | 0 | 20 |
| Total, serious adverse events | HCTZ | 0 | 15 |
Source ClinicalTrials.gov
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| K23AG030057 | Aging and The Renin-Angiotensin System in Elderly Hypertensive Individuals | HAJJAR, IHAB M | UNIVERSITY OF SOUTHERN CALIFORNIA | NATIONAL INSTITUTE ON AGING | 2007 to 2011 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Digit Span Test | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
| Verbal Learning | Primary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00605072
GET https://conductscience.org/api/trials/v1/NCT00605072/registered